The U.S. oligonucleotide synthesis market size is anticipated to reach USD 3.09 billion by 2030 and is projected to grow at a CAGR of 12.80% from 2024 to 2030. The rising demand for molecular diagnostics, emerging novel applications, and growing demand for oligonucleotide therapeutics owing to the emerging potential for incurable indications such as cardiovascular diseases, retinal disorders, and cancer are anticipated to increase the demand for oligonucleotide synthesis over the forecast period.
The COVID-19 pandemic has had a positive impact on the U.S. oligonucleotide synthesis industry. During the pandemic, however, the demand for oligonucleotide synthesis grew as pharmaceutical companies and healthcare professionals focused on identifying more efficient usage of oligonucleotides and their application to limit the spread of COVID-19. For instance, the Innovative Genomic Institute stated in 2020 that it was developing an aerosolized, locked nucleic acid modifying antisense oligonucleotide that can be breathed or nebulized to treat COVID-19 infection. Such advances piqued the interest of healthcare providers. Hence, the pandemic has had a favorable impact on the U.S. market.
Moreover, companies have increased investments to develop oligonucleotide-based therapeutics. For instance, in October 2023, GSK plc and Arrowhead Pharmaceuticals announced a contract with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, to assign GSK the exclusive worldwide rights to develop and commercialize JNJ-3989. Janssen initially in-licensed JNJ-3989 (previously ARO-HBV) from Arrowhead in 2018. Similar initiatives by well-established pharmaceutical companies are anticipated to drive market growth over the forecast period.
However, oligonucleotide synthesis encounters challenges and problems in practical applications, even with high-potential applications. One of the most critical parameters to get a high yield from synthesis is monitoring its coupling efficiency. Even the slightest rate of failure in average coupling causes dramatic effects in long sequences. A minor change in average coupling failure leads to a substantial net effect. Thus, real-time monitoring of each custom synthesis becomes essential for every platform and, thereby, is anticipated to hamper the growth of the market to a certain extent.
The COVID-19 pandemic has had a positive impact on the U.S. oligonucleotide synthesis industry. During the pandemic, however, the demand for oligonucleotide synthesis grew as pharmaceutical companies and healthcare professionals focused on identifying more efficient usage of oligonucleotides and their application to limit the spread of COVID-19. For instance, the Innovative Genomic Institute stated in 2020 that it was developing an aerosolized, locked nucleic acid modifying antisense oligonucleotide that can be breathed or nebulized to treat COVID-19 infection. Such advances piqued the interest of healthcare providers. Hence, the pandemic has had a favorable impact on the U.S. market.
Moreover, companies have increased investments to develop oligonucleotide-based therapeutics. For instance, in October 2023, GSK plc and Arrowhead Pharmaceuticals announced a contract with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, to assign GSK the exclusive worldwide rights to develop and commercialize JNJ-3989. Janssen initially in-licensed JNJ-3989 (previously ARO-HBV) from Arrowhead in 2018. Similar initiatives by well-established pharmaceutical companies are anticipated to drive market growth over the forecast period.
However, oligonucleotide synthesis encounters challenges and problems in practical applications, even with high-potential applications. One of the most critical parameters to get a high yield from synthesis is monitoring its coupling efficiency. Even the slightest rate of failure in average coupling causes dramatic effects in long sequences. A minor change in average coupling failure leads to a substantial net effect. Thus, real-time monitoring of each custom synthesis becomes essential for every platform and, thereby, is anticipated to hamper the growth of the market to a certain extent.
U.S. Oligonucleotide Synthesis Market Report Highlights
- Services dominated the product & service segment with the largest revenue share of 37.34% in 2023. This is attributed to the growing demand for specialized services. As the complexity of genomic research and therapeutic applications increases, researchers & companies are turning to outsourcing for the synthesis, purification, and customization of oligonucleotide sequences. On the other hand, oligonucleotide are expected to grow at the fastest rate over the forecast period.
- The PCR primers held the largest market share in 2023 for the application segment. Unique PCR primer allows labs to detect tiny quantities of DNA or RNA from pathogens, assisting in the identification of infectious diseases, including viral, bacterial, and parasitic infections. On the other hand, sequencing is expected to grow at the fastest rate over the forecast period.
- Based on end use, academic research institutes dominated the segment with the largest revenue share of 43.16% in 2023. This is attributed to the increasing number of clinical studies, which are being conducted in academic institutes and the growing funding for research activities. On the other hand, pharmaceutical & biotechnology companies are anticipated to grow at the fastest CAGR over the forecast period.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Market Variables, Trends, & Scope
Chapter 4. U.S. Oligonucleotide Synthesis Market: Product & Service Business Analysis
Chapter 5. U.S. Oligonucleotide Synthesis Market: Application Business Analysis
Chapter 6. U.S. Oligonucleotide Synthesis Market: End-use Business Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- Merck KGaA
- Danaher Corporation
- Dharmacon Inc.
- Agilent Technologies
- Bio-synthesis
- LGC Biosearch Technologies
- Twist Bioscience
- TriLink BioTechnologies
- Genscript
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 90 |
| Published | May 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 1.36 Billion |
| Forecasted Market Value ( USD | $ 3.09 Billion |
| Compound Annual Growth Rate | 12.8% |
| Regions Covered | United States |
| No. of Companies Mentioned | 10 |
